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The central role of Raf protein kinase isoforms in human cancer demands specific anti-Raf therapeutic
inhibitors. Parvoviruses are currently used in experimental cancer therapy due to their natural oncotropism
and lytic life cycle. In searching for mechanisms underlying parvovirus oncolysis, we found that trimers of the
major structural protein (VP) of the parvovirus minute virus of mice (MVM), which have to be imported into
the nucleus for capsid assembly, undergo phosphorylation by the Raf-1 kinase. Purified Raf-1 phosphorylated
the capsid subunits in vitro to the two-dimensional pattern found in natural MVM infections. VP trimers
isolated from mammalian cells translocated into the nucleus of digitonin-permeabilized human cells. In
contrast, VP trimers isolated from insect cells, which are devoid of Raf-1, were neither phosphorylated nor
imported into the mammalian nucleus. However, the coexpression of a constitutively active Raf-1 kinase in
insect cells restored VP trimer phosphorylation and nuclear transport competence. In MVM-infected normal
and transformed cells, Raf-1 inhibition resulted in cytoplasmic retention of capsid proteins, preventing their
nuclear assembly and progeny virus maturation. The level of Raf-1 activity in cancer cells was consistent with
the extent of VP specific phosphorylation and with the permissiveness to MVM infection. Thus, Raf-1 control
of nuclear translocation of MVM capsid assembly intermediates provides a novel target for viral oncolysis.
MVM may reinforce specific therapies against frequent human cancers with deregulated Raf signaling.
The Raf protein isoforms (A, B, C, or Raf-1) belong to the
conserved Ras/Raf/MEK/ERK mitogen-activated protein ki-
nase (MAPK) signaling module. This signal cascade transduces
mitogenic and other stimuli from the cell surface to the nucleus
(reviewed in reference 41). Activation of the Raf kinases is
primarily triggered by increased levels of the upstream regu-
lator Ras-GTP protein, which directly binds and recruits cyto-
solic dimers of the Raf kinases to the plasma membrane (58).
The membrane-associated Raf kinases are activated by phos-
phorylation and other events (48), assembling a MAPK signal-
ing complex formed by the MEK and ERK kinases and scaffold
proteins (8). Upon phosphorylation and dimerization (25), an
active ERK kinase dissociates from the complex and translo-
cates into the nucleus. Intranuclear ERK kinase promotes mul-
tiple protein phosphorylations and changes of gene expression
that may be altered in oncogenic and deregulated signaling
(50, 55).
The selectivity of lytic viruses in anticancer therapies depends
on cellular targets that favor their growth. Many if not all viral
infections interfere with major cellular protein kinase networks,
promoting virus entry, repressing antiviral responses, or increas-
ing metabolic activity and virus yield. The effects are, however,
virus dependent: viral activation of the MAPK signaling pathway,
for example, may induce cell proliferation (oncogenic DNA virus
[64]), suppress transcription (hepatitis B virus [83]), reactivate
translation (Ebola virus [71]), or enhance nuclear export (influ-
enza virus [52]). The MAPK signaling cascade is essential for
cellular proliferation and cancer formation (40, 67), which led to
the use of lytic viruses dependent on this pathway (7) in ongoing
preclinical and clinical trials (51). Molecular insights into the
interactions between viral substrates and components of the
MAPK pathway could thus increase specificity and therapeutic
efficacy of oncolytic viruses.
The replication of virus members of the Parvoviridae relies
on functions provided by proliferative cells (24). Together with
diverse factors that are linked to the neoplastic growth, the
underlying mechanisms allow parvoviruses to infect and lyse
transformed cells preferentially (47), thus interfering with tu-
mor formation in animal models (14, 74; reviewed in refer-
ences 11 and 54). The complex molecular mechanisms support-
ing parvovirus intrinsic oncotropism cannot be explained by either
suitable receptors responsible for virus uptake or the cytotoxicity,
which is triggered by the viral nonstructural proteins (5). Parvo-
virus productive infection is rather mediated on different levels of
the viral life cycle in a cancer-type-specific manner (65, 66). Par-
voviruses may provoke death of tumor cells lacking p53 (57, 73)
and show increased toxicity to transformed cells with upregulated
Ras and other protein kinases (49, 69).
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Progeny parvovirus production, which is required for the
spreading of oncolytic effects, depends on nuclear import of de
novo-synthesized structural (VP) proteins, since virion matu-
ration is intranuclear. The parvovirus capsid is composed of 60
protein subunits sharing a common C terminus folded in an
eight-strand antiparallel -barrel motif (76). In mammalian
cells infected with the parvovirus minute virus of mice (MVM),
capsid assembly starts by cytoplasmic synthesis of two types of
VP1/VP2 trimers in stoichiometric amounts (61). Nuclear
translocation of the trimers is driven by an unconventional
structured nuclear localization motif (NLM) evolutionary con-
served in the parvovirus -barrel (37). This NLM is exposed on
the trimer surface but not on the assembled capsid (37, 61).
Self-assembly into viruslike particles (VLPs) may occur after
expression of the parvovirus major capsid protein in heterolo-
gous systems (see, for example, references 20 and 82), although
little is known of the host factors regulating the nuclear tar-
geting and assembly of parvovirus capsid subunits.
The NLM sequence and configuration differs from the best-
characterized nuclear localization signals (NLS) causing pro-
tein cargo translocation across the nuclear envelope (NE).
Nucleocytoplasmic transport of proteins in eukaryotic cells is a
saturable and energy-dependent process occurring via the nu-
clear pore complex (NPC [4, 75]), a supramolecular structure
embedded in the NE. The bidirectional exchange of macro-
molecules across the NE is mostly mediated by proteins of the
importin  (karyopherin ) superfamily that comprises import-
ins (including transportins and snurportins) and exportins.
Cargo recognition is facilitated by direct or indirect interaction
with specialized signals, such as an NLS or a nuclear export
signal (NES) (44). In the classical nuclear import pathway,
karyopherin 1/importin  binds to the adaptor importin ,
which interacts with cargoes carrying NLS consisting of clusters
of basic amino acids (22, 28, 62). However, many imported
proteins bind karyopherin 1 directly without an adaptor, and
there are diverse nonclassical NLS that have structural or lin-
ear nonhomologous domains (9, 32). A well-characterized
nonclassical import pathway is mediated by karyopherin 2/
transportin, which binds different substrates, such as the splic-
ing factor hnRNP A1 (53), carrying the long and structurally
disordered NLS termed PY-NLS (29, 31). Independent of the
transport receptor, the directionality of the transport is driven
by the concentration gradient of the small GTPase Ran in its
GTP- and GDP-bound form, which triggers the dissociation of
the transport complexes and the release of the cargoes (re-
viewed in reference 70).
The missing conclusiveness to explain increased parvovirus
productive infection in cancer cells by receptors or cytotoxicity
of the nonstructural proteins, led us search for underlying
molecular mechanisms. To identify molecular targets of par-
vovirus oncolysis, we focused on the regulation of MVM as-
sembly in normal and cancer cells. The nuclear transport com-
petence and phosphorylation stage of isolated VP trimers was
compared in insect and human cells. We sought the mamma-
lian kinase involved and found that VP proteins phosphoryla-
tion by the Raf-1 kinase of the MAPK cascade is essential in
the nuclear translocation and capsid formation of MVM as-
sembly intermediates. The implications of these findings for
MVM anticancer therapeutic potential are discussed.
MATERIALS AND METHODS
MVMp and mammalian cells. The prototype strain of the autonomous par-
vovirus MVM (MVMp) (13), which infects mouse fibroblasts and human tumor
cells (47, 65, 72), was used. Production of viral stocks by transfection with the
pMM984 infectious plasmid (72), titration of infectivity by plaque assay, and
CsCl purification of native empty or DNA-full MVMp particles were performed
as previously described (43).
The human HeLa cell line (ATCC CCL2) and the C6 rat (ATCC CCL 107)
and U-373MG (ATCC HTB17) tumor glioma cells were purchased from the
American Type Culture Collection (ATCC) and maintained as previously de-
scribed (65). The mouse A9 fibroblasts and the human NB324K simian virus
40-transformed newborn kidney fibroblasts are commonly used cell lines in
MVM infections (72, 43). All cells of mammalian origin were maintained under
a minimal number of passages in Dulbecco modified Eagle medium (DMEM)
supplemented with 5% heat-inactivated fetal calf serum (FCS; Gibco-BRL) and
synchronized wherever indicated by low serum growth (A9) or density arrest
(NB324K and U-373MG) (to be described elsewhere). The Raf inhibitor Radi-
cicol (Calbiochem) was stored in frozen aliquots (70°C) and used at a 8 M
final concentration in the cultures. A9 cells stably expressing human Raf-1 with
the C-terminal sequence CAAX, which constitutively activates the kinase by
anchoring it to the cytoplasmic membrane (33), were obtained by cotransfection
with pSV2neo and subsequent selection of clones by Geneticin G418 (Gibco).
Baculoviruses and insect cells. Sf9 and H5 insect cells were cultured at 27°C
in TC100 medium supplemented with 5% FCS. Recombinant baculoviruses of
the Autographa californica (AcMNPV) species, expressing wild-type (wt) MVMp
VP2 (Bac-VP2wt) or VP2-K153A (Bac-VP2K153A), were previously described
(20, 59). Baculoviruses expressing wt Raf-1 and the Raf-22W constitutively active
mutant form (79, 80) were obtained from T. M. Roberts (Dana-Farber Cancer
Institute, Boston, MA). Baculoviruses were grown in Sf9 cells and titrated as
PFU (20) or as fluorescence focus units (36). For recombinant protein expres-
sion, growing Sf9 or H5 cells were infected at a multiplicity of infection of 10
PFU/cell for each baculovirus and harvested at 72 h postinfection (hpi; unless
indicated). VLPs of MVMp were purified from AcMNPV-VP2-infected insect
cells according to previously described protocols (20).
Purification of MVM assembly intermediates. NB324K human cells trans-
fected on a large scale by electroporation (36) using the VP2-K153A expression
plasmid (59) or H5 insect cells infected with baculoviruses were harvested in cold
HNEM buffer (50 mM HEPES [pH 8.0], 150 mM NaCl, 2 mM MgCl2, 1 mM
EDTA) supplemented with the protease inhibitor cocktail set I (Calbiochem),
100 g of TPCK (tolylsulfonyl phenylalanyl chloromethyl ketone) (Roche)/ml,
and phosphatase inhibitors (20 mM glycerol phosphate, 5 mM NaF). Cells were
disrupted in a cooled water bath sonicator, lysates were cleared by centrifugation
at 15,000  g and 4°C for 30 min in a benchtop centrifuge, and trimers from
insect cells were enriched by consecutive 20 and 30% ammonium sulfate pre-
cipitations. Cellular homogenates were loaded onto 14 ml of a 5 to 20% contin-
uous sucrose gradient in HNEM buffer prepared on ice and centrifuged at
160,000  g in a SW40 rotor (Beckman) at 5°C and 30 h, with molecular size
markers centrifuged in parallel gradients (61). Proteins in the fractions were
precipitated with 10% trichloroacetic acid and 10 g of bovine serum albumin
(BSA)/ml, resuspended in Laemmli buffer, and subjected to SDS-PAGE and
immunoblot analyses with anti-MVM sera. Fractions containing VP trimers (9S)
were pooled, dialyzed against transport buffer (see below), concentrated by a
Centricon-50 kDa (Millipore), and stored frozen in aliquots at 70°C until use.
The yield was approximately 2 to 5 g of purified VP-trimer per 107 cells.
Nuclear transport assay in permeabilized cells. Previously described method-
ologies (1, 18, 56) were followed with minor modifications. HeLa cells were
permeabilized with 40 g of digitonin (Sigma)/ml in DMEM for 5 min at 37°C.
Permeabilization was controlled by light microscopy before the cells were washed
three times for 10 min at 4°C in transport buffer (2 mM magnesium acetate, 20
mM HEPES [pH 7.3], 110 mM potassium acetate, 1 mM EDTA, 5 mM sodium
acetate, 2 mM dithiothreitol) containing 0.5% BSA and 5% goat serum (Gibco).
Import reactions were performed for 15 min at 37°C in 30 l of transport buffer
containing 12 mg of rabbit reticulocyte lysate (Promega)/ml, protease inhibitors
(as described above), 1 mM ATP, 5 mM creatine phosphate (Sigma), and 20 U
of creatine phosphokinase (Calbiochem)/ml. Substrates were 200 ng of gradient-
purified MVM capsid or VP trimers. As transport controls, BSA conjugated with
the SV-40 TAg NLS (PKKKRKVED) of the / classical importin route, and the
M9 domain (YNNQSSNFGPMK) of the transportin route (9, 22, 31), were used.
Peptides were conjugated to BSA coupled with fluor agents (Alexa Fluor 488,
594, and 647; Molecular Probes) by the chemical cross-linker SMCC (Calbio-
chem), cleaned by chromatography in PD10 columns (Amersham), and concen-
trated by centrifugation through filters (3-kDa Microcon; Millipore), as de-
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scribed previously (18). A ratio of 10 bound peptides per BSA molecule was
estimated by determining the protein molecular sizes by SDS-PAGE. For inhi-
bition of the nuclear import, wheat germ agglutinin ([WGA] Calbiochem), a
lectin that blocks glycosylated sites on the NPC that are required for interaction
with the nuclear import receptors (17), was added at 100 g/ml in the transport
reaction and washing buffer. The transport reaction was terminated by placing
the cells on ice, followed by three washes with transport buffer and fixation in 4%
paraformaldehyde.
Immunological analyses. Antibodies to components of the MAPK signaling
pathway (Santa Cruz Biotechnology) included mouse monoclonal (m-Raf) and
rabbit polyclonal (-Raf) antibodies recognizing the conserved C terminus of
human Raf-1; rabbit polyclonal antibody (p-ERK) recognizing the ERK1/2
proteins, and mouse monoclonal antibody (m-P-ERK) recognizing their phos-
phorylated forms. A mouse monoclonal antibody (-NPC) (MAb414; Babco,
Richmond, CA) was used as marker of the nuclear envelope. Human casein
kinase II was immunoprecipitated with an anti-CKIIa polyclonal antibody (Santa
Cruz Biotechnology). Antibodies raised against MVM capsid antigens previously
described (36, 61) included a rabbit polyclonal antiserum (polyclonal antibody
-capsid) raised against intact purified MVM empty capsids, the B7 mouse
monoclonal antibody recognizing a discontinuous epitope specific of the MVM
intact capsid (M-capsid) located at the threefold axes (23) that allows to
monitor capsid formation (37, 43), and a rabbit polyclonal antiserum raised
against denatured VP2 protein (-VPs) for the general localization of VP1 and
VP2 capsid proteins subunits (to be described elsewhere). Indirect double-label
immunofluorescence was performed by using secondary antibodies conjugated to
Texas Red or fluorescein isothiocyanate (FITC) (36), and phenotypes were
visualized by epifluorescence in a Zeiss Axiovert 200 microscope equipped with
a Radiance 2000 confocal laser scanning system (43). Pictures were recorded
with lasers giving excitation lines at 488 nm (FITC, filter HQ 500-530), and 543
nm (TXRD, filter HQ 600 LP). For Western blot analysis, protein samples
resolved in SDS–8% PAGE and electroblotted onto nitrocellulose membranes
were probed with the indicated antisera as described previously (61).
Raf-1 phosphorylation of MVM capsid subunits in mammalian cells and in
vitro. For [32P]orthophosphate in vivo labeling, MVMp-infected cells (5 PFU/
cell) were starved for 4 h at 6 hpi in phosphate-free medium with 10% dialyzed
FCS and labeled 10 to 24 hpi by the addition of 1 mCi of carrier-free
[32P]orthophosphate (Amersham)/ml. Capsid proteins were precipitated at 4°C
by using polyclonal anti-VPs antibodies bound to protein A-Sepharose in 150
mM NaCl–50 mM Tris (pH 8.0)–0.3% SDS–1% NP-40–0.75% 2-mercaptoetha-
nol and protease and phosphatase inhibitors prior to SDS-PAGE analysis. For in
vitro phosphorylation, the indicated kinases were immunoprecipitated with an-
tibodies from human NB324K cells at 4°C in 150 mM NaCl–50 mM Tris-HCl
(pH 7.5)–0.05% SDS–1% NP-40–0.5% deoxycholate in the presence of protease
and phosphatase inhibitors. The Sepharose-bound precipitate was stored at
70°C. The phosphorylation reaction was performed at 37°C for 30 min in 40 l
containing immunocomplex from 106 cells, 8 g of purified VLP in [-32P]ATP
(10 Ci [Amersham], 3,000 Ci/mmol), 0.1 M rATP, 25 mM HEPES (pH 7.4),
25 mM glycerophosphate, 1 mM dithiothreitol, and 10 mM MgCl2. The 32P-
labeled VP2 protein resolved in gels was blotted to nitrocellulose membranes
(BA85; Schleicher & Schuell) and subjected to two-dimensional tryptic phos-
phopeptide analysis in 20-by-20-cm thin-layer chromatography plates (Merck,
Darmstadt, Germany) according to previously reported procedures (42). The
plates were exposed to a radioanalytic imaging system (Fujix BAS 1000; Fuji) or
to X-ray films with intensifying screens for 4 days.
Analysis of MVM capsid protein phosphorylation in insect cells. 32P labeling
of VP2 protein and VLPs in Sf9 and H5 insect cells infected by baculoviruses was
attempted for periods of 6 h at either 22, 38, or 48 hpi in TC100 medium
without phosphate and 5% dialyzed FCS supplemented with 0.5 to 1 mCi of
[32P]orthophosphate carrier-free (Amersham)/ml at 8,500 Ci/mmol. Okadaic
acid (Gibco), a phosphatase inhibitor (3), was used at 350 nM during the last
hour of labeling to prevent the removal of putative transient phosphate groups.
VLPs were purified from the 32P-labeled cultures by CsCl gradient centrifugation
to equilibrium (42). Fractions were tested for 32P counts and hemagglutination
activity (20), and those corresponding to empty MVM particles were pooled and
dialyzed. Detection of phospho label in the purified VP2 protein was repeatedly
attempted by separating 5 g of gradient-purified VLPs by SDS-PAGE and
exposure to autoradiography with intensifying screens for 7 days. To examine the
level of VP2wt and VP2K153A protein phosphorylation in the presence of
baculovirus-coexpressed Raf-1 proteins, the 32P-labeled H5 cell monolayers were
subjected to immunoprecipitation with the -VPs and -Raf-1 antibodies as
described above.
RESULTS
Trimers of MVM capsid subunits assembled in insect cells
are not competent for nuclear transport. In mammalian cells
susceptible to the parvovirus MVM, the capsid proteins (VPs)
accumulate intranuclear (12, 37) (see also Fig. 4B below). In
contrast, most baculovirus-transduced insect cells, which do
not support replication of this mammalian virus, exhibited an
exclusive cytoplasmic localization of the VPs (Fig. 1A, upper
panels). Particle-specific antibodies characterized by slot blot
analyses (see Fig. 1B) showed that, in contrast to mammalian
FIG. 1. MVM capsid trimers accumulate in the cytoplasm of insect
cells. (A) Subcellular distribution of MVM structural (VP2) protein
(wt and K153A mutant) and capsid in H5 insect cells infected with the
indicated recombinant baculoviruses. (B) Antibody specificity for
MVM antigens. Capsid and VP trimers gradient-purified from human
cells (see Materials and Methods) were applied to nitrocellulose mem-
branes in phosphate saline buffer (PBS), and their immunoreactivity
was analyzed by slot blot analyses. Note the lack of reactivity of VP
trimers with the monoclonal -capsid antibody, a finding in agreement
with the inability of the trimers to conform in cells the capsid-specific
epitope (23, 61). Capsid and VP trimers are efficiently recognized by
the -VPs polyclonal antibody. (C) Purification of VP trimers from
insect cells. Extracts of Bac-VP2-K153A-infected H5 cells subjected to
ammonium sulfate precipitations were sedimented in sucrose gradients
and analyzed by SDS-PAGE and immunoblotting. Representative re-
sults of VP2 distribution in sucrose gradients (including monomers,
trimers, and high-molecular-weight aggregates) loaded with total H5
cellular homogenate (upper) or 20% ammonium sulfate precipitate
(middle) or in the supernatant of 30% ammonium sulfate precipitation
(lower) are shown. The 17 S marker sedimented to the bottom of the
gradients.
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cells, VLPs self-assembled inefficiently and primarily local-
ized in the perinuclear cytosolic region (Fig. 1A). This find-
ing, which confirmed previous reports on MVM (20) and
canine parvovirus (82) assembly in insect cells, not only
showed a cell-type-specific transport but also indicated a
different assembly competence.
To avoid the possibility that capsid formation in the cyto-
plasm may interfere with the nuclear transport competence of
VP trimers, the major assembly intermediate (61), we used the
VP2-K153A mutant. This mutant forms trimers that are nu-
clear import competent in mammalian cells but do not assem-
ble into capsids (61). Expression of this mutant in H5 insect
cells showed a cytoplasmic phenotype with nuclear exclusion
(Fig. 1A, lower panels) as for the wt VP2. Cytoplasmic capsid
formation was thus not responsible for the lack of VP2 nuclear
import in insect cells. Since nuclear VP2 (or VP2-K153A)
localization depends on trimer formation (61), we sought to
determine whether insect cells are competent for VP2 trimer-
ization. Both wt and K153A mutant proteins expressed in in-
sect cells sedimented with the velocity of VP2 trimers by ana-
lytical sucrose gradient ultracentrifugation (Fig. 1C) and could
further be chemically cross-linked as described previously (61;
data not shown). Collectively, these findings indicate that the
failed VP2 nuclear translocation in insect cells was not deter-
mined by impaired trimer formation.
Active nuclear import of VP trimers isolated from human
cells. Although the nuclear transport process is evolutionarily
well conserved, there are some differences between distantly
related organisms, since some proteins are imported into the
nucleus in a species-dependent manner (10). To exclude that
such phenomena cause the lack of import of the VP trimers in
insect cells, we purified VP2-K153A trimers from NB324K
human and H5 insect cells and tested them with digitonin-
permeabilized human HeLa cells. Transport was facilitated by
import receptors that are present in rabbit reticulocyte lysate,
which supports nuclear entry in various permeabilized mam-
malian cell lines. A control experiment was performed using
native empty capsids purified from MVM-infected cells. Con-
sistent with the localization of the NLM in the internal capsid
surface (37), no capsids were detectable within the nucleus of
the HeLa cells (Fig. 2A, upper panels). However, human cell
line-derived VP2 trimers translocated into the nucleus. In
agreement with our previous report (61), this result provided
further direct evidence of the important role that the VP tri-
meric intermediate plays in MVM capsid assembly. Transport
was temperature dependent, indicating active nuclear import
(Fig. 2A middle panels). Active receptor-mediated transport
was confirmed by using the nuclear import inhibitor WGA
(Fig. 2A, lower panels). In contrast, H5 insect cell-expressed
trimers failed to accumulate in HeLa nuclei even under trans-
port supporting conditions (Fig. 2B).
Site-specific VP2 phosphorylation by Raf-1 in vitro. In
searching for the mechanism underlying the different nuclear
transport competence of mammalian and insect VP trimers, we
investigated the role of phosphorylation, known to be a major
regulator of cargo-receptor interactions in nuclear import (60).
We observed that wt VLPs and VP2-K153A trimers purified
from H5 and Sf9 insect cells showed no detectable phospho
label, irrespective of the conditions of metabolic labeling (see
Materials and Methods). In contrast, the VP capsid subunits
from MVM-infected human and mouse cells are phosphory-
lated (42, 43). Phosphorylation occurred mainly at Ser-2, -6,
and -10 of the VP2 N-terminal domain (2Nt) (42), overlapping
with within two contiguous S/TXXXS/T canonical activation
loop motifs of the MAPK signaling pathway (40, 78). To ex-
plore whether differences in the MAPK signaling pathway be-
tween insect and mammalian cells can account for the different
VP2 phosphorylation, we subjected insect cell-derived VP2 to
in vitro phosphorylation assays with human Ser/Thr protein
kinases after precipitation by different antibodies. We focused
on the Raf family (A-Raf, B-Raf, and C-Raf [or Raf-1]), which
are involved in the development of a high proportion of gli-
oma, melanoma, and other human malignancies (15, 16, 38, 78,
77), by promoting the nuclear translocation of phosphorylated
downstream effectors (16, 41). As a control, CKII was used
since it affects the nuclear transport capacity of some NLS-
containing proteins (60).
Intact VLP could not be phosphorylated, irrespective of the
anti-protein kinase antibody used for pulldown. In contrast,
heat-disassembled capsid underwent substantial phosphoryla-
FIG. 2. VP trimers isolated from mammalian and insect cells differ
in their nuclear transport competence. (A) Confocal analysis of the
nuclear transport of mammalian VP trimers in permeabilized cells.
Equal amounts of MVM capsid (upper) and VP trimer (lower) puri-
fied from NB324K human cells were incubated with permeabilized
HeLa cells and stained with the -VPs antibody. (B) Transport assay
with VP-trimers isolated from human NB324K (mammal) or H5 (in-
sect) cells in the presence of fluorescent BSA-M9 of the transportin
pathway.
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tion by Raf-1 and by CKII and, to lower extent, by the P-ERK
kinase (Fig. 3A). The two-dimensional phosphopeptide pat-
tern obtained with Raf-1 (Fig. 3B) was remarkably identical to
the pattern of VP2 with native empty capsids purified from
MVM-infected cells (42, 43). In contrast, P-ERK and CKII
phosphorylations analyzed by two-dimensional chromatogra-
phy lacked the characteristic prominence of phosphopeptide B
(data not shown). These results indicate that Raf-1 can directly
phosphorylate VP2 at the sites and to a similar extent found in
MVM infections, but on unassembled protein subunits only.
Raf-1 phosphorylation of capsid assembly intermediates is
required for MVM productive infection. The MVM capsid
surface lacked Raf-1 phosphorylation sites but these sites be-
came exposed on heat-treated capsid (Fig. 3A and B). The
exposure of Raf-1 phosphorylation sites on MVM capsid dis-
assembly intermediates was further analyzed in vitro by using
purified intact VLPs subjected to graded heat-induced confor-
mational rearrangements. MVM native capsid and VLPs un-
dergo conformational changes along a 60 to 90°C temperature
range that can be monitored by fluorescence (6) and are asso-
ciated with the externalization out of the coat of the VP2 2Nt
that becomes accessible to trypsin digestion (20). As shown in
Fig. 3C, the VP2 phosphorylation by Raf-1 gradually increased
when the samples had been heated to temperatures that cause
partial or total VLP disassembly. It is noteworthy that Raf-1
only phosphorylated residues heat externalized out of the coat
in VP2 domains fully accessible to the protease. At the lower
temperatures of 60 to 75°C, these phosphorylated residues
were localized in the 2Nt domain, since they were removed
from the capsid as the VP2 protein was cleaved by trypsin to
produce VP3. This experiment confirmed that 2Nt, the major
phosphorylated domain of MVM capsid in infected cells (42),
is also a main target of Raf-1 phosphorylation in vitro.
The assembly-dependent exposure of Raf-1 phosphorylation
sites in vitro suggested that VP phosphorylation in cells must
occur prior to capsid assembly, which follows VP nuclear im-
port (61). To confirm the latter hypothesis in vivo, the effect of
Raf-1 activity on VP transport and assembly was investigated.
We used Radicicol, which selectively depletes Raf kinase (68).
Inhibitor treatment instead of a genetic silencing approach was
chosen since permanent Raf-1 inhibition affects cell prolifera-
tion, which is mandatory for parvovirus replication (24). The
inhibitor was added on synchronous cultures of three MVMp
permissive cells with different origins and tumorigenic poten-
tials, at postinfection times and in a concentration that allowed
both effective Raf-1 depletion and accumulation of capsid pro-
teins to high levels (Fig. 4A). The Radicicol treatment caused
a significant cytosolic retention of the VP proteins that was
partial in human NB324K and mouse A9 fibroblasts (Fig. 4B
and C) and absolute in U373 glioma cells (Fig. 4D). The
different degrees of VP transport inhibition among the cell
lines occurred consistently, for reasons that were not further
investigated. However, a severely reduced capsid formation
was consistently observed in all three cell cultures (Fig. 4B to
FIG. 4. Inhibition of Raf-1 impairs MVM nuclear capsid assembly.
Synchronous cultures infected with MVMp were released from the
arrest and treated () or not () with Radicicol (Rad) at 14 hpi.
(A) Accumulation of Raf-1 and of VP proteins along the infection of
NB324K cells shown by Western blots. (B to D) Confocal analysis of
the subcellular distribution of VP proteins and MVM capsid in normal
and Raf-1-inhibited (Rad) cells at 20 hpi. (B) NB324K transformed
human fibroblasts; (C) A9 mouse fibroblasts; (D) U373 human glioma.
FIG. 3. Raf-1 phosphorylation of MVM assembly intermediates in
vitro. (A) Phosphorylation of VP2 subunits of native (VLP) or heated-
denatured (VLPh) VLPs by immunoprecipitated kinases. Autoradiog-
raphy after SDS-PAGE is shown. (B) Two-dimensional phosphopep-
tide map of the VP2 protein phosphorylated in vitro by pulldown
Raf-1. Phosphopeptides are named according to a previous nomencla-
ture (42). (C) Raf-1 phosphorylation of MVM capsid disassembly
intermediates. Purified wtVLP particles heated at the indicated tem-
peratures were subjected to Raf-1 phosphorylation (see Materials and
Methods) and, wherever indicated (), to subsequent trypsin digestion
at 37°C as described previously (20, 42). Samples were resolved by
SDS–8% PAGE and electroblotted, and filters were exposed to auto-
radiography (upper) and subsequently developed with the anti-VPs
antibody (lower).
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D, -capsid/Rad panels), corresponding to an inhibition in
infectious virus yields by1,000-fold within a single replication
cycle (data not shown). Collectively, these results indicated
that inhibition of Raf-1 signaling cascade interferes with the
nuclear accumulation of VP proteins, which is a prerequisite
for capsid assembly (61). Consistently, a severe impairment of
MVM capsid formation and progeny virus production was ob-
served.
Raf-1 phosphorylation confers nuclear transport compe-
tence to the VP trimer. To directly relate Raf-1 phosphoryla-
tion to the nuclear transport of MVM capsid proteins, we used
insect cell-expressed VP2 trimers coexpressed with the wt
or with a constitutively active form of the Raf-1 kinase (Raf-
22W). Expression of Raf-22W was performed since—in con-
trast to mammalian cells—insect cells require the coexpression
of p21ras, pp60v-src, or JAK2 oncoproteins to obtain full wt
Raf-1 activation (79, 81). Phosphorylation of the VP2 protein
in the insect cells was evaluated by in vivo labeling with
[32P]orthophosphate. VP2 phosphorylation was almost unde-
tectable in baculovirus infections even under a very high level
of accumulation of phosphorylated wt Raf-1 protein (Fig. 5A).
However, wt and K153A mutant VP2 proteins were phosphor-
ylated to similarly high levels in insect cells coexpressing the
constitutively active Raf-22W protein (Fig. 5A, middle and
lower panels). We next purified such phosphorylated VP2 tri-
mer and its nonphosphorylated equivalent and analyzed their
transport competence. In agreement with the results shown in
Fig. 2, the nonphosphorylated VP2 trimer did not enter the
nuclei of digitonin-permeabilized HeLa cells (Fig. 5B, upper
panels). In contrast, VP2 trimers isolated from Raf-22W-ex-
pressing insect cells were efficiently and actively imported (Fig.
5B, lower panels). We thus concluded that Raf-1 phosphory-
lation confers nuclear transport competence to the VP2 trimer
in mammalian cells.
Raf-1 activity in mouse and human transformed cells in-
creases permissiveness to MVM infection. We finally investi-
gated the relationship between Raf-1 activity and the susceptibil-
ity to MVM infection and oncolysis. The simian virus 40-
transformed human NB324K and the mouse A9 fibroblasts are
two common MVM cell hosts (72). Virus production was signif-
icantly higher in the NB324K cells (43, 72), which corresponded
to an increased degree of VP2-specific phosphorylation (43). We
thus analyzed whether Raf-1 activation correlated with these
parameters. Figure 6A demonstrates that the amount of Raf-1
was similar in both fibroblast cell lines. Activation of the
MAPK signaling pathway was, however, higher in NB324K
FIG. 5. Raf-1 phosphorylation suffices VP2 trimer for nuclear im-
port. (A) VP2 phosphorylation by Raf-1 in insect cells. H5 cells in-
fected with the indicated baculoviruses were labeled at 22 to 28 hpi
with [32P]orthophosphate. The upper section blot shows VP2 and
Raf-1 expression in the [32P]orthophosphate-labeled cultures. For the
middle panel, autoradiography of the same filter was performed. The
lower panel shows phosphorylation of VP2wt and VP2-K153A proteins
in Raf-22W-expressing insect cells demonstrated by immunoprecipita-
tion with the -VPs antibody. Approximately 105 labeled cells were
subjected to each analysis. (B) Confocal laser scanning microscopy of
the nuclear transport of phosphorylated VP2 trimer in mammalian
cells. Gradient-purified VP2 trimers from insect cells infected by the
Bac-VP2wt (VP trimer) or by the Bac-VP2wt and the Bac-Raf1-22W
baculoviruses (VP trimer-P) were subjected to transport analysis in
permeabilized HeLa cells. The lower panels show the results of a
control experiment with permeabilized cells kept on ice showing no
significant nuclear localization caused by diffusion.
FIG. 6. Activation of the MAPK signaling cascade in MVM per-
missive cells. (A) Levels of Raf-1, and of phosphorylated ERK protein
isoforms, accumulated in the indicated cell lines, as determined by
SDS-PAGE and immunoblotting. Cells were starved 24 h with low
serum and stimulated 6 h with 10% FCS before harvest. Equivalent
graded amounts of total protein extracts were loaded per slot. (B) Pat-
tern of VP2 phosphorylation in glioma cells. The figure shows two-
dimensional phosphopeptide maps of VP2, immunoprecipitated from
the indicated MVM-infected glioma cells labeled with [32P]orthophos-
phate. Scale bar, 2 cm.
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cells. To exclude a cell-type-specific activation that is indepen-
dent to permissiveness, we further analyzed the human U373
and the rat C6 glioma cell lines, which are both highly permis-
sive to MVM cytotoxicity and productive infection (65). Both
glioma cells exhibited MAPK signaling pathway activation
(Fig. 6A) that corresponded to the characteristic VP2 phos-
phorylation pattern found in MVM infections (Fig. 6B). Of
note, phosphopeptide B, representing the VP2 2Nt (42), was
particularly prominent in the human U3T3 glioma cells. Con-
clusively, the levels of Raf-1 activation corresponded with in-
creased virus production and VP2-specific phosphorylation in
MVM permissive transformed fibroblasts and glioma cells.
To gain direct evidence that an activated Raf-1 does increase
cell permissiveness to MVM, mouse A9 cells were stably trans-
fected with the constitutively active RafCAAX mutant (33).
Two clones transfected by the RafCAAX expression vector
harboring an increased Raf-1 activity with respect to the pa-
rental A9 cells were selected (Fig. 7A). Upon MVM infection,
these clones showed a moderately enhanced VP phosphoryla-
tion (Fig. 7B). Moreover, the two-dimensional phosphopeptide
map of the expressed VP2 (Fig. 7C) remained identical to that
found after infection of the parental A9 cells (43).
Raf-1 activation thus enhanced VP2 specific phosphoryla-
tion in vivo. To correlate the extent of Raf-1 phosphorylation
with the level of productive infection, we analyzed MVM
plaque-forming capacity in the parental and Raf-1-transfected
A9 cells. As shown in Fig. 7D, the higher extent of VP2 phos-
phorylation in RafCAAX-expressing cells correlated well with
a three- to fourfold increase in the number of MVMwt plaques
formed in the transfected clones. For further confirmation, we
infected these cells with an MVMp mutant harboring the three
serine residues targeted by Raf-1 at the 2Nt domain mutated to
glycine (42). This mutant (S/G) lacking 2Nt phosphorylation
grows poorly but can be purified from NB324K cells (42),
although it can form clear plaques in A9 fibroblasts (43). In
contrast to the wt, this mutant showed no significant alteration
in its plaque phenotype (regarding both number and size of the
plaques) comparing A9 and A9-RafCAAX cells (Fig. 7D,
right). Thus, a constitutively active Raf-1 does not enhance the
plaque-forming capacity of a MVM mutant lacking the target
Ser residues at 2Nt.
DISCUSSION
Lack of MVM capsid protein phosphorylation in insect
cells. Most vertebrate proteins expressed by baculoviruses in
insect cells are correctly phosphorylated. However, quantita-
tively altered and nonphysiological phosphorylation sites were
described for a number of mammalian virus proteins (21, 34).
The lack of MVM capsid protein phosphorylation in insect
FIG. 7. Raf-1 activity increases cell permissiveness to MVM infection. (A) Activity of the MAPK signaling pathway in untransfected and
RafCAAX transfected A9 mouse fibroblasts, as measured by blot analysis of the basal and phosphorylated ERK1/2 isoforms. (B) Level of VP
phosphorylation in MVMp-infected A9 and A9-RafCAAX cells. VP proteins immunoprecipitated at 20 hpi from 32P-labeled cells were separated
by SDS-PAGE and blotted. Filters were exposed to autoradiography (left) and then probed with the -VPs antibody (right). (C) Two-dimensional
phosphopeptide map of the VP2 protein in MVM-infected A9-RafCAAX cells. Major phosphopeptides are marked according to an earlier study
(42). Scale bar, 2 cm. (D) Comparative plaque-forming capacity of wt MVM and of the S/G mutant in normal A9 cells and in two A9-RafCAAX-
transfected clones. Cell monolayers were inoculated in parallel with wtMVM and S/G viral samples normalized for PFU titers, and plaques were
scored in triplicate. Means with the standard errors from four assays are shown.
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cells described in the present study is thus uncommon. It was
unexpected given the overall MAPK signaling pathway conser-
vation in evolution, including the Raf homolog (Draf) found in
Drosophila melanogaster (46). Although Draf contains all three
conserved Raf domains, its sequence similarity to Raf-1 is lower
across their N-terminal regulatory region (35), suggesting that
insect Raf proteins may be not homologous enough to interact
with and phosphorylate VP2. Our results are consistent with the
requirement of coexpressed oncoproteins of this pathway in in-
sect cells for mammalian Raf-1 activation (79–81).
Raf-1 phosphorylation regulates the MVM life cycle. The
Raf-1 kinase plays an essential role in MVM cycle, since Raf-1
activity increased MVM infection (Fig. 6 and 7). The site-
specific in vitro phosphorylation of fully and partly disassem-
bled VLP protein subunits by Raf-1 (Fig. 3) strongly suggests
that newly synthesized VP proteins in MVM-infected mam-
malian cells are phosphorylated by the normally cytoplasmic
Raf-1 kinase (33). Raf-1 phosphorylation was required (Fig. 2)
and sufficient (Fig. 5) to confer competence for nuclear trans-
location to the VP subunits. Phosphorylation was thus needed
for the interaction of VP trimers with nuclear transport factors.
The mechanism by which Raf-1 phosphorylation enhances NE
translocation of MVM assembly intermediates is in agreement
with the largely recognized association of parvovirus infections
with mitogenic and proliferative cell processes (2, 24).
In insect cells devoid of Raf-1 activity, VP2 proteins lacking
any phospho label (Fig. 3A and 5A and data not shown) self-
assembled into cytoplasmic VLPs but rather inefficiently (Fig.
1A), as was previously shown for the canine parvovirus (82).
We further show here that the VP2 proteins accumulate as
trimers and large aggregates in the insect cytoplasm (Fig. 1C).
Therefore, VP phosphorylation may be also important in the
orchestrated parvovirus morphogenesis, in particular at the
stage of assembly of the trimeric intermediate into the T	1
capsid. Interestingly, the capsid subunits must indeed undergo
a conformational change along this stage of the assembly pro-
cess, since trimers expressed in cells (61) (Fig. 1A) or isolated
as protein complex in vitro (Fig. 1B) failed to configure the
epitope recognized by the B7 monoclonal antibody at the
threefold axis of the capsid (23). VP phosphorylation may
facilitate this conformational change or the recognition of the
trimers by a morphogenetic cellular factor. However, VLPs
were shown to exhibit the same three-dimensional crystal
structure as native phosphorylated MVM capsid (20, 27, 42),
indicating that phosphorylation does not shape the final con-
figuration of the amino acid residues in the formed capsid.
Raf-1 targeting in MVM anticancer potential. The Raf ki-
nase isoforms are frequently overexpressed, activated, or mu-
tated in glioma, melanoma, and pancreatic carcinomas (15, 16,
38, 77, 78). The findings that Raf-1 phosphorylation (i) plays a
key role in the nuclear entry of MVM capsid assembly inter-
mediates, (ii) is required for virus maturation, and (iii) sup-
ports propagation of the lytic infection in glioma and other
human transformed cells is thus supporting current searches
for inhibitors of the Raf signaling cascade for cancer treatment
(19, 45, 63). Disruption of the Raf-1–Rb interaction by RRD-
251 suppresses tumor growth (26), and Sorafenib or Nexavar
(Bayer 43-9006), designed to counter Raf kinases, is currently
in phase III clinical trials for melanoma treatment and is ap-
proved for metastatic renal cancer (30). However, concerns
about the specificity and efficacy of these inhibitors in the clinic
were raised, since therapeutic benefit may be caused by side
inhibition of V-EGFR needed for angiogenesis (reviewed in
reference 39) and Raf-1 may be activated as consequence of
B-Raf inhibition (77). Parvoviruses, which show antineoplastic
activity in animal models (11, 54), may thus become alternative
and more specific agents in combined therapies against certain
cancer types. Our results support MVM, a mouse parvovirus
that is apathogenic for humans, as a cytotoxic and replicative
inhibitor targeting common cancers with a deregulated Raf
signaling cascade.
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